Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843374 · ClinicalTrials.gov registry record · Phase 2
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
A Phase 2 study of Unresectable Pleural or Peritoneal Malignant Mesothelioma, sponsored by MedImmune.
- Active
- Registry status
- Phase 2
- Development phase
- 571
- Enrollment target
- 20
- Study locations
NCT01843374: Active Phase 2 study of Unresectable Pleural or Peritoneal Malignant Mesothelioma, sponsored by MedImmune.
NCT01843374 is a Phase 2 study of Unresectable Pleural or Peritoneal Malignant Mesothelioma that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 571 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (329% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01843374, a Phase 2 study of Unresectable Pleural or Peritoneal Malignant Mesothelioma, is active but no longer recruiting, sponsored by MedImmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 571 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.
Primary Outcome
Overall survival (OS) by treatment arm
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tremelimumab
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - San Francisco
- Research Site - Santa Monica
Illinois
- Research Site - Chicago
- Research Site - Peoria
Maryland
- Research Site - Baltimore
- Research Site - Baltimore
New York
- Research Site - New York
- Research Site - Rochester
Arizona
- Research Site - Scottsdale
Connecticut
- Research Site - New Haven
Delaware
- Research Site - Newark
Florida
- Research Site - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 571 participants |
| Start Date | 2013-05-17 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What the registry record for NCT01843374 still lists
NCT01843374 is an interventional study that assigns participants to a tested intervention. The registered 571 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (329% higher).
The record links to 1 condition, with Unresectable Pleural or Peritoneal Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01843374 names 20 study sites across 14 states, led by California, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT01843374 about?
NCT01843374 is a clinical study titled "Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma". This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries....
What is the current status of trial NCT01843374?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 571 participants. The study started on 2013-05-17. Estimated completion is 2026-06-30.
What conditions does trial NCT01843374 study?
This clinical trial studies the following conditions: Unresectable Pleural or Peritoneal Malignant Mesothelioma.
What interventions are being tested in trial NCT01843374?
The interventions under investigation include: Placebo (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT01843374?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01843374 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01843374's enrollment target sits among peer trials
571 59th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04410796 · 571 participants · Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- NCT05131022 · 572 participants · Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- NCT06346392 · 572 participants · Phase 3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- NCT06615050 · 572 participants · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI